Compare MYRG & LEGN Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | MYRG | LEGN |
|---|---|---|
| Founded | 1891 | 2014 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Water Sewer Pipeline Comm & Power Line Construction | Biotechnology: Pharmaceutical Preparations |
| Sector | Industrials | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 4.0B | 4.6B |
| IPO Year | 2008 | 2020 |
| Metric | MYRG | LEGN |
|---|---|---|
| Price | $273.33 | $16.30 |
| Analyst Decision | Strong Buy | Buy |
| Analyst Count | 6 | 14 |
| Target Price | ★ $367.50 | $40.93 |
| AVG Volume (30 Days) | 283.7K | ★ 2.4M |
| Earning Date | 10-28-2026 | 11-10-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ 311.48 | N/A |
| EPS | ★ 9.97 | N/A |
| Revenue | ★ $1,531,169,000.00 | N/A |
| Revenue This Year | $24.47 | $38.78 |
| Revenue Next Year | $14.89 | $17.61 |
| P/E Ratio | $26.81 | ★ N/A |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $199.31 | $15.75 |
| 52 Week High | $503.57 | $37.50 |
| Indicator | MYRG | LEGN |
|---|---|---|
| Relative Strength Index (RSI) | 47.78 | 36.01 |
| Support Level | $250.39 | N/A |
| Resistance Level | $290.32 | $19.92 |
| Average True Range (ATR) | 13.82 | 1.40 |
| MACD | 0.81 | -0.74 |
| Stochastic Oscillator | 59.27 | 8.25 |
MYR Group Inc is a U.S. based holding company of specialty electrical construction service providers. Through its subsidiaries, it serves electric utility, commercial, and industrial construction markets in the United States and Canada, offering services such as design, engineering, procurement, construction, upgrades, maintenance, and repair, with a focus on construction, maintenance, and repair work. The company operates through two segments: Transmission and Distribution (T&D) and Commercial and Industrial (C&I). The majority of revenue is derived from the T&D segment, which provides a range of services on electric transmission and distribution networks and substation facilities, which include design, engineering, procurement, construction, upgrade and maintenance and repair services.
Legend Biotech Corp is a clinical-stage biopharmaceutical company. It is engaged in the discovery and development of novel cell therapies for oncology and other indications. The firm's product candidate, LCAR-B38M/JNJ-4528, is a chimeric antigen receptor, or CAR, T cell therapy for the treatment of multiple myeloma. Geographically, the company generates a majority of its revenue from the United States of America. The company generates revenue from License and Collaboration revenue.